The Biological Half-Time of Hageman Factor

Summary

The biological half-time of factor XII was assessed (a) after transfusion of freshly-drawn, normal intact ACD-plasma into a patient having Hageman trait and suffering from polycythaemia vera, and (b) with blocked synthesis in a patient suffering from acute liver dystrophy due to phosphoric intoxication. The results obtained suggest that the biological half-time under normal conditions has a value between 50 and 70 hrs.

• References

• 1 Borchgrevink C. F, Egeberg O, Pool J. G, Skulason T, Storniorken H, Waaler B. A study of a case of congenital hypoprothrombinaemia. Brit. J. Haemat. 5: 294 1959;
• 2 Caen J, Yanotti S, Varangot J, Bernard J. Étude d’un cas d’hypoproconvertinémie vraie congénitale. Sang 30: 535 1959;
• 3 Esch B. van der. Coagulation studies in patients receiving excessively large amounts of vitamin K antagonists. Thesis, Leiden 1966
• 4 Fantl P. Repair of cardale defect in a patient with Ehlers-Danlos syndrome and deficiency of Hageman Factor. Brit. med. J. I: 1202 1961;
• 5 Goolden A. W. G, Gartside J. M, Szur L. Changes in interstitial fluid in polycythaemia vera. Clin. Sci. 25: 441 1962;
• 6 Hammond J. D. S, Verel D. Observations on the distribution and biological half life of human fibrinogen. Brit. J. Haemat. 5: 431 1959;
• 7 Hardisty R. M, Macpherson J. C. A one-stage factor VIII (antihaemophilic globulin) assay and its use on venous and capillary plasma. Thrombos. Diathes. haemorrh. (Stuttg.) 7: 215 1962;
• 8 Hensen A, Loeliger E. A. Antithrombin III, its metabolism and its function in blood coagulation. Thrombos. Diathes. haemorrh. (Stuttg.) Suppl. 10 1963
• 9 Ingram G. I. C, Pinniger J. L, Vallet L. Survival in a afibrinogenaemic subject of fibrinogen prepared from “time-expired” blood. Lancet I: 135 1960;
• 10 Larrieu M. J, Soulier J. P, Culot Y. Déficit en facteur Hageman. Sang 28: 152 1957;
• 11 Loeliger E. A, Hensen A. Substitution therapy in haemophilia B. Thrombos. Diathes. haemorrh. (Stuttg.) 6: 391 1961;
• 12 Loeliger E. A, Veltkamp J. J, Mattern M. J, Hooij H. J. Disposable plastic cuvettes for thrombelastography. Thrombos. Diathes. haemorrh. (Stuttg.) 9: 519 1963;
• 13 Loeliger E. A, van der Esch B, Hemker H. C, Mattem M. J. The biological disappearance rate of prothrombin, factor VII, IX, and X from plasma in hypothyroidism, hyperthyroidism, and during fever. Thrombos. Diathes. haemorrh. (Stuttg.) 10: 267 1964;
• 14 Loeliger E. A, Hensen A, Veltkamp J. J, van der Meer J, Hemker H. C. On the metabolism of factor IX.. Internat. Symp. on Haemophilia, Washington 1963. The University of N. Carolina Press; Chapel Hill, U.S.A.: 1964
• 15 Loeliger E. A, Mattem M. J, Hemker H. C. Transfusion of coumarin induced hypopro-thrombinaemic plasma into a patient suffering from severe congenital hypoprothrombinaemia. Thrombos. Diathes. haemorrh. (Stuttg.) In preparation
• 16 Ramot B, Singer K, Heller P, Zimmerman H. J. Hageman factor (HF) deficiency. Blood 11: 745 1956;
• 17 Ratnoff O. D, Colopy J. E. A familial haemorrhagic trait associated with a deficiency of a clot promoting fraction of plasma. J. clin. Invest. 34: 602 1955;
• 18 Schnitger H. Entwicklung eines neuartigen Gerätes zur automatischen Registrierung von Blutgerinnungszeiten und kritischer Beitrag zur Theorie anderer Meβprinzipien für gerinnungsphysiologische Untersuchungen. Thesis, Marburg 1956
• 19 Veitkamp J. J. The detection of the carrier state in hereditary coagulation disorders. Thesis, Leiden 1966